Could a Parkinson's drug ease symptoms of a rare childhood brain condition?

This study tests whether L-dopa, a drug used for Parkinson's, can improve movement and communication in children with a rare genetic disorder called CTNNB1 syndrome. The condition causes developmental delays, muscle stiffness, and trouble walking. Seven children aged 1 to 15 will receive L-dopa for 6 to 12 months, and researchers will measure changes in motor skills using a standard scale.